How should capital allocate across U.S. life sciences real estate in 2026 given the post-2022 vacancy reset, the hypothesized shift from lab-office toward cGMP / validated production environments, and the widening gap between established clusters and emerging Texas nodes?

Life sciences is no longer a generic growth story. In 2026 it is a basis-and-cluster story. The best capital should separate three buckets: established Tier 1 clusters that remain strategically dominant but are still digesting oversupply, Tier 2 clusters where the pipeline has shut off and basis may now be more attractive than the headline vacancy implies, and emerging Texas nodes that are strategically important but not yet broad institutional deployment markets.

The Source Collection: CBRE Insights Market Reports Public Crawl 2026 adds review-level support to that allocation frame. Its life-sciences rows reinforce reset conditions and pipeline contraction, while the medical-outpatient rows belong more to healthcare real estate diligence than lab-office allocation. Because this is a small cluster and several rows still need source checks or normalization, it should update the page's caveats rather than override the existing DB-backed Boston / San Diego / Raleigh-Durham comparison.

Source: JLL 2026 U.S. Lab Property Report now preserves JLL's own public report page behind the earlier secondary lab-availability signal. The visible JLL body supports a bottoming / early-recovery read, but not a broad risk-on allocation: availability has started contracting after peaking in 2025, demand is rebounding in key markets, flight-to-quality is accelerating, and elevated supply still pressures rents and leasing behavior. Keep this separate from MOB / outpatient medical facility evidence and from table-grade C&W, CBRE, and Transwestern source-family rows.

The June 2026 GlobeSt metadata captures add a narrower public-description layer to the same watch item. GlobeSt described lab availability as contracting after the correction while still noting tenant-friendly conditions from the prior development surge, and separately described San Diego as seeing its best venture-capital pace since 2021 with positive first-quarter absorption despite high availability. Because the captures expose metadata and descriptions rather than full article bodies, use them as directional flags only; they should not overwrite the DB-backed Q3/Q4 2025 vacancy and pipeline metrics. See Source: GlobeSt Life Sciences Recovery After Lab Space Correction 2026 and Source: GlobeSt San Diego Life Sciences VC Pace 2026.

Source: Cushman & Wakefield U.S. Life Sciences MarketBeat Q1 2026 adds the first current source-preserved C&W national table to this allocation page. It confirms that the 2026 setup is still a reset, not a broad beta recovery: U.S. vacancy was 23.6%, asking rent was down 3.4% year over year, and Q1 absorption was essentially flat. The investable improvement is supply and capital-formation based: deliveries slowed sharply, 72% of the under-construction pipeline was build-to-suit, sublease vacancy declined slightly, VC funding improved to $8.0B, and IPO activity strengthened.

Source: CBRE Q1 2026 U.S. Life Sciences Figures triangulates the same reset with a different denominator. CBRE's top-13 lab/R&D summary reported 23.2% vacancy, negative absorption across nine of 13 major markets totaling 1.2M SF, $67.30/SF average NNN rent, 4.7M SF under construction, and $7.4B of Q1 VC funding. The allocation implication is unchanged but sharper: improving biotech capital formation is not enough by itself. Broad lab-office exposure still needs a rent / downtime / tenant-credit discount, while new-money deployment should favor cluster depth, validated production, BTS credit, or basis resets rather than generic beta.

Source: Transwestern U.S. Market Life Sciences Q1 2026 adds a third Q1 2026 source-family read. Its qualified-inventory denominator reported 275.9M SF of U.S. inventory, 13.5% direct vacancy, -462,974 SF of Q1 net absorption, $53.50/SF NNN asking rent, and 13.4M SF under construction. That does not overturn the reset thesis because the same report shows negative current-quarter absorption and uneven market performance; it instead tightens the denominator warning and adds a first structured Houston row for Texas life-sciences diligence.

Source: CBRE 2026 U.S. Life Sciences Trends adds the forward-looking CBRE outlook companion to the Q1 figures. It supports the page's basis-and-cluster posture by saying demand has stabilized, lab / R&D construction is projected to hit a 10-year low, capital is re-engaging, and transaction activity may gain momentum in key markets as policy uncertainty and financing conditions improve. That is a watchlist and entry-timing signal, not a broad upgrade for all lab-office inventory.

Source: Colliers Life Sciences Market Outlook 2026 adds the Colliers qualitative version of the same disciplined-growth thesis. The public landing page says venture capital has normalized, speculative construction has slowed, tenant demand is focusing on premier lab environments in leading innovation hubs, and Boston, San Francisco, and San Diego continue to attract institutional capital and top-tier tenants despite elevated vacancy in select secondary markets. Because the full report download was not directly retrievable during intake, use this as source-family confirmation of cluster selectivity and supply moderation, not as a numeric ranking, vacancy, rent, absorption, pipeline, or VC dataset.

The allocation split is explicit: Boston and San Diego have the deepest cluster proof but still need submarket and basis discipline; Raleigh-Durham is a reset-market opportunity because vacancy is high while new supply has stopped; Philadelphia and selected low-vacancy markets deserve follow-up diligence under C&W's source family; Texas is earlier-stage coverage where institutional anchors matter but the source layer does not yet support broad market-rate lab deployment.

Source: CBRE Boston Metro Life Science Figures Q1 2026 adds the current Boston-specific CBRE source-family row. Greater Boston lab availability held at 32.7%, vacancy was 27.9%, Q1 absorption was still negative at -117,186 SF, and cumulative negative absorption since Q1 2025 exceeded 1.1M SF. That is marginally better than Q4 2025 absorption but not a broad recovery signal; it reinforces the page's view that Boston remains Tier 1 by cluster depth while generic lab-office exposure still needs basis, downtime, tenant-credit, and submarket controls.

Source: CBRE New York City Life Sciences Figures Q1 2026 adds a New York-specific CBRE source-family row. The visible page shows weak current demand rather than a scaled deployment market: 27,000 SF of Q1 leasing velocity, 27.5% lab-exclusive availability, $96.43/SF lab-exclusive asking rent, and $263.65M of quarterly VC funding. NYC belongs in the Northeast watchlist / peer-comparison set, but this source does not justify moving it into the main allocation buckets without inventory, pipeline, tenant-depth, and submarket proof.

Source: CBRE Denver/Boulder Life Sciences Figures Q1 2026 adds a smaller Front Range comparator. Denver/Boulder showed 85,000 SF of Q1 leasing activity, 282,000 SF of rolling four-quarter leasing, 12.7% direct vacancy, 18.4% Boulder vacancy, $205M of Q1 VC funding, and only 221,000 SF in the pipeline. That supports an emerging-cluster watchlist lane: better current vacancy than the loose coastal reset markets, but still too thin for broad institutional allocation without inventory, rent, tenant-credit, and submarket proof.

• The 2021-2022 lab boom is over. Vacancy is now high enough in Boston, San Diego, and Raleigh-Durham that no market should be underwritten as if lab demand is still supply-constrained across the board.
• Cluster strength still matters more than cheapness. Boston and San Diego remain the two strongest deployable clusters in this source set because tenant density, research anchors, and regulatory stickiness are real even while the market is resetting. Boston / Cambridge has the global biotech depth and capital ecosystem; San Diego has a West Coast biology cluster with sharper submarket dispersion between Torrey Pines / UTC and Sorrento Mesa / Sorrento Valley.
• Pipeline shutoff matters. Raleigh-Durham's most important number is not just 32.3% vacancy; it is 0 SF under construction. That is what makes the market interesting for capital willing to buy through the reset.
• Texas is a strategic option on future depth, not yet a proven broad allocation market. The source trail is strong on campus formation and institutional anchors, but weak on rents, vacancy, and transaction evidence compared with Boston, San Diego, and RTP.
• South San Francisco now has a standalone draft geography node, but it is still intentionally not given its own bucket here because the source layer remains thinner than Boston, San Diego, and RTP and does not yet support a comparably defensible allocation call.

• Boston is best for capital that wants the deepest global biotech cluster and can be patient on lease-up. It is weakest for investors who need near-term mark-to-market rent momentum.
• San Diego is best for capital that can distinguish Torrey Pines and UTC from Sorrento Mesa's larger spec overhang. It is weaker for buyers treating the whole market as one uniform lab corridor.
• Raleigh-Durham is best for opportunistic investors who want a real life sciences ecosystem without paying Boston or San Diego basis. It is weaker for investors who require a currently tight market rather than a reset market.
• Houston works for strategic capital that believes institutional healthcare and research anchors can compound into a real life sciences district around TMC. It is weaker for anyone pretending Houston already has the same depth as the coastal clusters.
• Dallas works for early thematic capital that values Pegasus Park's incubator-to-graduation pathway. It is weakest for large capital that needs immediate market depth and a fully formed tenant base.

The most important underwriting hypothesis is that demand is moving away from speculative lab-office as a generic venture-growth trade and toward cGMP manufacturing and validated production environments. The source trail supports this as a strategic direction, but data/properties.db does not yet distinguish lab-office from cGMP / manufacturing space, so the shift should be treated as a diligence thesis rather than a quantified market fact. That changes the allocation map:

• Boston and San Diego remain the primary R&D cluster markets, but broad office-like lab supply is still working through excess inventory.
• Raleigh-Durham looks more interesting today as a value and conversion market because its construction pipeline has already shut down.
• Houston and Dallas are more attractive as future manufacturing and institutional-anchor stories than as current pure-play lab-office markets, but they remain provisional qualitative nodes until market-rate vacancy, rent, absorption, and transaction data are preserved.

• Do not treat high vacancy in Boston or San Diego as proof that the cluster thesis broke. The source trail points to a supply-cycle reset, not a collapse in scientific relevance.
• Do not treat Texas campus formation as proof that Houston or Dallas are already scaled life sciences markets. The repo's Texas source note is explicit that the boom is "not quite there yet."
• Do not underwrite generic flex or office product as interchangeable with real life sciences space. Regulatory stickiness, MEP intensity, and TI reload risk still define the asset class.

This is the first national allocation note in the graph for a specialized asset class that already has both an underwriting page and a geography page. It turns Life Sciences and Lab Underwriting and Life Sciences Cluster Geography into a capital-deployment decision rather than leaving them as parallel reference pages.

• Analyses Hub
• Life Sciences Cluster Geography
• Life Sciences and Lab Underwriting
• South San Francisco Life Sciences Corridor
• Boston
• San Diego
• Charlotte and Raleigh-Durham
• Texas Medical Center District
• Dallas-Fort Worth

All figures sourced from data/properties.db market_observations. Geography filter: property_type = 'Life Sciences' or name LIKE '%Life%'. Sources: Hunneman / C&W / Colliers / Lincoln LPC (Boston); C&W / Savills / Newmark / CBRE (San Diego); C&W (Raleigh-Durham).

Submarket vacancy (Q3 2025, C&W): Torrey Pines 10.2% on 6.2M SF (tightest), UTC/Campus Point 16.6% on 3.6M SF, Sorrento Mesa 39.7% on 7.6M SF (highest), Sorrento Valley 38.0% on 1.6M SF.

Note: Savills flagged ~5 former Pfizer buildings expected to hit the market, potentially pushing wet lab availability to ~45%.

The pipeline-shutoff metric is Raleigh-Durham's most important structural signal: 0 SF under construction as of Q2 2025 means no new dilutive supply is coming even as vacancy resets toward a trough.

The DB now contains a Transwestern Q1 2026 source-family baseline for Houston life sciences, but not a Texas Medical Center-specific or Dallas life-sciences market-rate series. Houston should therefore move from "no structured observations" to "thin structured baseline": useful enough for a vacancy / rent / absorption check, not enough to underwrite broad Texas institutional deployment.

data/market_import_cw_us_life_sciences_marketbeat_q1_2026.json adds C&W source-family rows for the national market and 12 reported markets. The national row now preserves 239.5M SF of inventory, 23.6% vacancy, $65.48/SF weighted asking rent, -23,659 SF of Q1 absorption, 1.18M SF of Q1 deliveries, 5.35M SF under construction, 72% BTS pipeline share, $2.1B of R&D property sales, $8.0B of venture funding, and eight IPOs raising more than $2.3B. Market rows add C&W-labeled vacancy, asking rent, absorption, leasing, inventory, deliveries, and under-construction observations for Boston, Chicago, Denver, Los Angeles-Orange County, New Jersey, New York City, Philadelphia, Raleigh-Durham, San Diego, San Francisco Bay Area, Seattle, and Suburban Maryland.

data/market_import_cbre_us_life_sciences_figures_q1_2026.json adds seven CBRE source-family rows from the visible public Q1 2026 U.S. Life Sciences Figures page. The national top-13 lab/R&D row preserves 23.2% vacancy, a 30 bps QoQ vacancy increase, -1.2M SF of negative net absorption across nine of 13 major markets, $67.30/SF average NNN asking rent, 4.7M SF under construction, and $7.4B of Q1 VC funding. A separate Los Angeles row preserves CBRE's 700K SF project-start callout. Use these rows as directional CBRE triangulation against C&W's broader table, not as a same-denominator market replacement.

data/market_import_transwestern_us_life_sciences_q1_2026.json adds Transwestern source-family rows for the national market and 11 visible markets. The national row preserves 275.9M SF of inventory, 13.5% direct vacancy, -462,974 SF of Q1 net absorption, 923,499 SF of 12-month net absorption, $53.50/SF NNN asking rent, -3.0% annual asking-rent change, 13.4M SF under construction, $7.1B of Q1 venture funding across 101 deals, six IPOs raising $1.6B, and $7.15B of 2026 YTD NIH distributions. Market rows add vacancy, rent, absorption, 12-month absorption, inventory, rent-change, and construction observations for Boston, Chicago, Houston, New Jersey, New York, Philadelphia, Raleigh/Durham, Phoenix, San Diego, San Francisco, and Washington DC.

• Dallas life sciences market data: Dallas still has no vacancy, rent, or absorption observations in the DB. Houston now has a Transwestern source-family baseline, but no Texas Medical Center-specific or Dallas market-rate series. Texas allocation calls remain provisional relative to Boston, San Diego, Raleigh-Durham, and other table-backed markets.
• South San Francisco: A standalone corridor page now exists, but there are still no South-San-Francisco-specific observations in the DB. The current public evidence is mainly city cluster data plus San Mateo County proxy metrics, which is enough for geography routing but not for a standalone allocation bucket.
• Boston submarket breakdown: Cambridge is tracked separately in the DB, but other Boston-area submarkets (Route 128 corridor, Seaport, Waltham) have no individual geography entries. The metro vacancy divergence between Cambridge (12.7%) and the broader metro (28.8%) is notable but incompletely characterized.
• Capital markets / transaction data: C&W now provides a national $2.1B Q1 2026 R&D property sales-volume observation, but no market-level investment sales volume, cap rate, or price-per-SF observations exist in the DB. The basis-reset thesis for Boston and San Diego still cannot be quantified from current structured market-level data.
• cGMP and manufacturing space: The DB does not distinguish lab-office from cGMP/manufacturing space in any of the tracked markets. The allocation note's cGMP argument is a source-supported strategic hypothesis, not a quantified market series.
• Raleigh-Durham — Q3/Q4 2025 update: The most recent RTP observations are as of Q2 2025. No Q3 or Q4 2025 C&W or CBRE report has been imported yet.

• Boston Market Intelligence 2025
• San Diego Market Intelligence 2025-2026
• Raleigh-Durham Market Intelligence 2025
• Source: Life Sciences: The Next Frontier for Commercial Real Estate in Texas?
• South San Francisco Life Sciences Cluster 2025-2026
• Source: GlobeSt Life Sciences Recovery After Lab Space Correction 2026
• Source: GlobeSt San Diego Life Sciences VC Pace 2026
• Source: Cushman & Wakefield U.S. Life Sciences MarketBeat Q1 2026
• Source: CBRE Q1 2026 U.S. Life Sciences Figures
• Source: Transwestern U.S. Market Life Sciences Q1 2026
• Source: JLL 2026 U.S. Lab Property Report